Skip to content

Study · Animal study (in vivo) · mouse · 2018

16 results

Exenatide Delays the Progression of Nonalcoholic Fatty Liver Disease in C57BL/6 Mice, Which May Involve Inhibition of the NLRP3 Inflammasome through the Mitophagy Pathway.

Shao N, Yu XY, Ma XF, Lin WJ, Hao M, Kuang HY

Gastroenterology research and practice15 Apr 2018Cited by 50 (Europe PMC)

PMID29849583 (opens in a new tab)PMCIDPMC5925008 (opens in a new tab)DOI10.1155/2018/1864307 (opens in a new tab)PepBankPUB-29849583
Download PDFPubMedAsk about this study
Jump to 16 results

Summary

ObjectiveThis study is aimed at investigating whether exenatide (Exe) delays the progression of nonalcoholic fatty liver disease (NAFLD) in C57BL/6 mice by targeting the NLRP3 inflammasome through the autophagy/mitophagy pathway.MethodsThirty male C57BL/6 mice were randomly divided into three groups: control group (n = 10), model group (n = 10), and Exe (exenatide) group (n = 10). Mouse models of NAFLD and diabetes were established using a high-fat diet and streptozocin.ResultsThe levels of fasting blood glucose (FBG), total cholesterol (TC), and triglyceride (TG) in the serum were significantly reduced after Exe treatment. The body weight, liver weight/body weight, and number of lipid droplets in the liver significantly decreased in Exe-treated mice. Treatment with Exe markedly reduced the levels of liver lipids, malondialdehyde (MDA), and alanine aminotransferase (ALT) in serum and livers. The number of autophagosomes increased significantly in the Exe group. The expression of LC3A/B-II/I, Beclin-1, Parkin, and BNIP3L increased significantly, whereas NLRP3 and IL-1β proteins were suppressed after Exe treatment.ConclusionWe successfully established a mouse model of NAFLD and diabetes. Exe may reduce oxidative stress injury and inhibit the NLRP3 inflammasome by enhancing the autophagy/mitophagy pathway in liver, which has a protective effect on the liver in NAFLD and diabetes in C57BL/6 mice.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study16

16 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with NAFLD and diabetes, exenatide significantly reduced fasting blood glucose.

    In plain wordsIn mice with fatty liver disease and diabetes, exenatide lowered fasting blood glucose.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFasting blood glucose
    Study

    mousen: not reported in source

    C57BL/6 mice with high-fat diet and streptozocin-induced NAFLD and diabetes
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The levels of fasting blood glucose (FBG), total cholesterol (TC), and triglyceride (TG) in the serum were significantly reduced after Exe treatment.
    2 context sentences
    Summary · context
    Thirty male C57BL/6 mice were randomly divided into three groups: control group (n = 10), model group (n = 10), and Exe (exenatide) group (n = 10).
    Summary · context
    Mouse models of NAFLD and diabetes were established using a high-fat diet and streptozocin.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with NAFLD and diabetes, exenatide significantly reduced serum total cholesterol.

    In plain wordsIn mice with fatty liver disease and diabetes, exenatide lowered blood cholesterol.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseSerum total cholesterol
    Study

    mousen: not reported in source

    C57BL/6 mice with high-fat diet and streptozocin-induced NAFLD and diabetes
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The levels of fasting blood glucose (FBG), total cholesterol (TC), and triglyceride (TG) in the serum were significantly reduced after Exe treatment.
    2 context sentences
    Summary · context
    Thirty male C57BL/6 mice were randomly divided into three groups: control group (n = 10), model group (n = 10), and Exe (exenatide) group (n = 10).
    Summary · context
    Mouse models of NAFLD and diabetes were established using a high-fat diet and streptozocin.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with NAFLD and diabetes, exenatide significantly reduced serum triglycerides.

    In plain wordsIn mice with fatty liver disease and diabetes, exenatide lowered blood triglycerides.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseSerum triglycerides
    Study

    mousen: not reported in source

    C57BL/6 mice with high-fat diet and streptozocin-induced NAFLD and diabetes
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The levels of fasting blood glucose (FBG), total cholesterol (TC), and triglyceride (TG) in the serum were significantly reduced after Exe treatment.
    2 context sentences
    Summary · context
    Thirty male C57BL/6 mice were randomly divided into three groups: control group (n = 10), model group (n = 10), and Exe (exenatide) group (n = 10).
    Summary · context
    Mouse models of NAFLD and diabetes were established using a high-fat diet and streptozocin.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with NAFLD and diabetes, exenatide significantly reduced body weight.

    In plain wordsIn mice with fatty liver disease and diabetes, exenatide reduced body weight.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    mousen: not reported in source

    C57BL/6 mice with high-fat diet and streptozocin-induced NAFLD and diabetes
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The body weight, liver weight/body weight, and number of lipid droplets in the liver significantly decreased in Exe-treated mice.
    2 context sentences
    Summary · context
    Thirty male C57BL/6 mice were randomly divided into three groups: control group (n = 10), model group (n = 10), and Exe (exenatide) group (n = 10).
    Summary · context
    Mouse models of NAFLD and diabetes were established using a high-fat diet and streptozocin.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with NAFLD and diabetes, exenatide significantly reduced the liver weight/body weight ratio.

    In plain wordsIn mice with fatty liver disease and diabetes, exenatide reduced liver weight relative to body weight.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseLiver weight/body weight
    Study

    mousen: not reported in source

    C57BL/6 mice with high-fat diet and streptozocin-induced NAFLD and diabetes
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The body weight, liver weight/body weight, and number of lipid droplets in the liver significantly decreased in Exe-treated mice.
    2 context sentences
    Summary · context
    Thirty male C57BL/6 mice were randomly divided into three groups: control group (n = 10), model group (n = 10), and Exe (exenatide) group (n = 10).
    Summary · context
    Mouse models of NAFLD and diabetes were established using a high-fat diet and streptozocin.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice with NAFLD and diabetes, exenatide significantly reduced liver lipid droplet counts.

    In plain wordsIn mice with fatty liver disease and diabetes, exenatide reduced fat droplets in the liver.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseLiver lipid droplets
    Study

    mousen: not reported in source

    C57BL/6 mice with high-fat diet and streptozocin-induced NAFLD and diabetes
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The body weight, liver weight/body weight, and number of lipid droplets in the liver significantly decreased in Exe-treated mice.
    2 context sentences
    Summary · context
    Thirty male C57BL/6 mice were randomly divided into three groups: control group (n = 10), model group (n = 10), and Exe (exenatide) group (n = 10).
    Summary · context
    Mouse models of NAFLD and diabetes were established using a high-fat diet and streptozocin.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice with NAFLD and diabetes, exenatide markedly reduced liver lipid levels.

    In plain wordsIn mice with fatty liver disease and diabetes, exenatide reduced liver fat levels.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseLiver lipids
    Study

    mousen: not reported in source

    C57BL/6 mice with high-fat diet and streptozocin-induced NAFLD and diabetes
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with Exe markedly reduced the levels of liver lipids, malondialdehyde (MDA), and alanine aminotransferase (ALT) in serum and livers.
    2 context sentences
    Summary · context
    Thirty male C57BL/6 mice were randomly divided into three groups: control group (n = 10), model group (n = 10), and Exe (exenatide) group (n = 10).
    Summary · context
    Mouse models of NAFLD and diabetes were established using a high-fat diet and streptozocin.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In mice with NAFLD and diabetes, exenatide markedly reduced malondialdehyde levels in serum and liver.

    In plain wordsIn mice with fatty liver disease and diabetes, exenatide reduced malondialdehyde in blood and liver.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseMalondialdehyde
    Study

    mousen: not reported in source

    C57BL/6 mice with high-fat diet and streptozocin-induced NAFLD and diabetes
    Outcome group
    Inflammation markers · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with Exe markedly reduced the levels of liver lipids, malondialdehyde (MDA), and alanine aminotransferase (ALT) in serum and livers.
    2 context sentences
    Summary · context
    Thirty male C57BL/6 mice were randomly divided into three groups: control group (n = 10), model group (n = 10), and Exe (exenatide) group (n = 10).
    Summary · context
    Mouse models of NAFLD and diabetes were established using a high-fat diet and streptozocin.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In mice with NAFLD and diabetes, exenatide markedly reduced alanine aminotransferase levels in serum and liver.

    In plain wordsIn mice with fatty liver disease and diabetes, exenatide reduced alanine aminotransferase in blood and liver.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAlanine aminotransferase
    Study

    mousen: not reported in source

    C57BL/6 mice with high-fat diet and streptozocin-induced NAFLD and diabetes
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with Exe markedly reduced the levels of liver lipids, malondialdehyde (MDA), and alanine aminotransferase (ALT) in serum and livers.
    2 context sentences
    Summary · context
    Thirty male C57BL/6 mice were randomly divided into three groups: control group (n = 10), model group (n = 10), and Exe (exenatide) group (n = 10).
    Summary · context
    Mouse models of NAFLD and diabetes were established using a high-fat diet and streptozocin.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In mice with NAFLD and diabetes, exenatide significantly increased autophagosome counts.

    In plain wordsIn mice with fatty liver disease and diabetes, exenatide increased autophagosome counts.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseAutophagosome count
    Study

    mousen: not reported in source

    C57BL/6 mice with high-fat diet and streptozocin-induced NAFLD and diabetes
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The number of autophagosomes increased significantly in the Exe group.
    2 context sentences
    Summary · context
    Thirty male C57BL/6 mice were randomly divided into three groups: control group (n = 10), model group (n = 10), and Exe (exenatide) group (n = 10).
    Summary · context
    Mouse models of NAFLD and diabetes were established using a high-fat diet and streptozocin.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In mice with NAFLD and diabetes, exenatide significantly increased LC3A/B-II/I expression.

    In plain wordsIn mice with fatty liver disease and diabetes, exenatide increased LC3A/B-II/I expression.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseLC3A/B-II/I expression
    Study

    mousen: not reported in source

    C57BL/6 mice with high-fat diet and streptozocin-induced NAFLD and diabetes
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The expression of LC3A/B-II/I, Beclin-1, Parkin, and BNIP3L increased significantly, whereas NLRP3 and IL-1β proteins were suppressed after Exe treatment.
    2 context sentences
    Summary · context
    Thirty male C57BL/6 mice were randomly divided into three groups: control group (n = 10), model group (n = 10), and Exe (exenatide) group (n = 10).
    Summary · context
    Mouse models of NAFLD and diabetes were established using a high-fat diet and streptozocin.
  12. 12AnimalAnimal study (in vivo)Mechanism

    In mice with NAFLD and diabetes, exenatide significantly increased Beclin-1 expression.

    In plain wordsIn mice with fatty liver disease and diabetes, exenatide increased Beclin-1 expression.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseBeclin-1 expression
    Study

    mousen: not reported in source

    C57BL/6 mice with high-fat diet and streptozocin-induced NAFLD and diabetes
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The expression of LC3A/B-II/I, Beclin-1, Parkin, and BNIP3L increased significantly, whereas NLRP3 and IL-1β proteins were suppressed after Exe treatment.
    2 context sentences
    Summary · context
    Thirty male C57BL/6 mice were randomly divided into three groups: control group (n = 10), model group (n = 10), and Exe (exenatide) group (n = 10).
    Summary · context
    Mouse models of NAFLD and diabetes were established using a high-fat diet and streptozocin.
  13. 13AnimalAnimal study (in vivo)Mechanism

    In mice with NAFLD and diabetes, exenatide significantly increased Parkin expression.

    In plain wordsIn mice with fatty liver disease and diabetes, exenatide increased Parkin expression.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseParkin expression
    Study

    mousen: not reported in source

    C57BL/6 mice with high-fat diet and streptozocin-induced NAFLD and diabetes
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The expression of LC3A/B-II/I, Beclin-1, Parkin, and BNIP3L increased significantly, whereas NLRP3 and IL-1β proteins were suppressed after Exe treatment.
    2 context sentences
    Summary · context
    Thirty male C57BL/6 mice were randomly divided into three groups: control group (n = 10), model group (n = 10), and Exe (exenatide) group (n = 10).
    Summary · context
    Mouse models of NAFLD and diabetes were established using a high-fat diet and streptozocin.
  14. 14AnimalAnimal study (in vivo)Mechanism

    In mice with NAFLD and diabetes, exenatide significantly increased BNIP3L expression.

    In plain wordsIn mice with fatty liver disease and diabetes, exenatide increased BNIP3L expression.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseBNIP3L expression
    Study

    mousen: not reported in source

    C57BL/6 mice with high-fat diet and streptozocin-induced NAFLD and diabetes
    Outcome group
    Receptor activity and mechanism · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The expression of LC3A/B-II/I, Beclin-1, Parkin, and BNIP3L increased significantly, whereas NLRP3 and IL-1β proteins were suppressed after Exe treatment.
    2 context sentences
    Summary · context
    Thirty male C57BL/6 mice were randomly divided into three groups: control group (n = 10), model group (n = 10), and Exe (exenatide) group (n = 10).
    Summary · context
    Mouse models of NAFLD and diabetes were established using a high-fat diet and streptozocin.
  15. 15AnimalAnimal study (in vivo)Mechanism

    In mice with NAFLD and diabetes, exenatide suppressed NLRP3 protein.

    In plain wordsIn mice with fatty liver disease and diabetes, exenatide reduced NLRP3 protein.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseNLRP3 protein
    Study

    mousen: not reported in source

    C57BL/6 mice with high-fat diet and streptozocin-induced NAFLD and diabetes
    Outcome group
    Inflammation markers · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The expression of LC3A/B-II/I, Beclin-1, Parkin, and BNIP3L increased significantly, whereas NLRP3 and IL-1β proteins were suppressed after Exe treatment.
    2 context sentences
    Summary · context
    Thirty male C57BL/6 mice were randomly divided into three groups: control group (n = 10), model group (n = 10), and Exe (exenatide) group (n = 10).
    Summary · context
    Mouse models of NAFLD and diabetes were established using a high-fat diet and streptozocin.
  16. 16AnimalAnimal study (in vivo)Mechanism

    In mice with NAFLD and diabetes, exenatide suppressed IL-1β protein.

    In plain wordsIn mice with fatty liver disease and diabetes, exenatide reduced IL-1β protein.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseIL-1 beta protein
    Study

    mousen: not reported in source

    C57BL/6 mice with high-fat diet and streptozocin-induced NAFLD and diabetes
    Outcome group
    Inflammation markers · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The expression of LC3A/B-II/I, Beclin-1, Parkin, and BNIP3L increased significantly, whereas NLRP3 and IL-1β proteins were suppressed after Exe treatment.
    2 context sentences
    Summary · context
    Thirty male C57BL/6 mice were randomly divided into three groups: control group (n = 10), model group (n = 10), and Exe (exenatide) group (n = 10).
    Summary · context
    Mouse models of NAFLD and diabetes were established using a high-fat diet and streptozocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.